Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Inventory (2020 - 2025)

Maxcyte (MXCT) has disclosed Inventory for 6 consecutive years, with $7.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Inventory changed N/A to $7.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.6 million, a N/A change, with the full-year FY2024 number at $8.9 million, down 27.11% from a year prior.
  • Inventory was $7.6 million for Q3 2025 at Maxcyte, down from $8.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $12.2 million in Q4 2023 to a low of $4.1 million in Q3 2021.
  • A 5-year average of $8.2 million and a median of $8.1 million in 2022 define the central range for Inventory.
  • Peak YoY movement for Inventory: surged 90.71% in 2022, then plummeted 30.82% in 2025.
  • Maxcyte's Inventory stood at $5.2 million in 2021, then soared by 64.87% to $8.6 million in 2022, then soared by 42.52% to $12.2 million in 2023, then dropped by 27.11% to $8.9 million in 2024, then dropped by 14.62% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Inventory are $7.6 million (Q3 2025), $8.3 million (Q1 2025), and $8.9 million (Q4 2024).